Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

STROSUTRO BIOPHARMA, INC.

Nasdaq · CIK 0001382101
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts275

Identity from submissions API

NameSUTRO BIOPHARMA, INC.
CIK0001382101
TickersSTRO
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN452441988
LEI—
Fiscal year end1231
State of incorporation—
Phone650-392-8412
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • SUTRO BIOPHARMA INC (2009-03-11T04:00:00.000Z → 2018-11-08T05:00:00.000Z)
  • Fundamental Applied Biology Inc (2006-11-08T05:00:00.000Z → 2007-10-24T04:00:00.000Z)
Business address
111 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
CA
Mailing address
111 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

628 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-463816 005-90656 261562695 34 10892
2026-11-12 10-Q 10-Q 0001193125-26-458680 001-38662 261547963 34 13029590 1 1
2026-11-12 8-K 8-K 2.02,9.01 0001193125-26-458641 001-38662 261547814 34 351169 1 1
2026-11-09 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-124373 005-90656 261535117 34 24682
2026-09-22 4 xslF345X06/form4-09222026_080918.xml 0001992979-26-000004 9487
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-352649 005-90656 261283763 34 10989
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-005498 005-90656 261281585 34 12317
2026-08-12 10-Q 10-Q 0001193125-26-345748 001-38662 261265330 34 12754326 1 1
2026-08-12 8-K 8-K 2.02,7.01,9.01 0001193125-26-345733 001-38662 261265305 34 16017113 1 1
2026-07-30 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-003158 005-90656 261221142 34 10900
2026-06-09 4 xslF345X06/form4-06092026_080649.xml 0001587487-26-000002 5804
2026-06-09 4 xslF345X06/form4-06092026_080650.xml 0001294939-26-000002 5803
2026-06-09 4 xslF345X06/form4-06092026_080620.xml 0001217412-26-000002 5818
2026-06-09 4 xslF345X06/form4-06092026_080653.xml 0001536193-26-000002 5851
2026-06-09 4 xslF345X06/form4-06092026_080605.xml 0001554591-26-000002 5839
2026-06-09 4 xslF345X06/form4-06092026_080631.xml 0001891841-26-000002 5842
2026-06-09 4 xslF345X06/form4-06092026_080646.xml 0001601264-26-000006 5830
2026-06-09 4 xslF345X06/form4-06092026_080655.xml 0001236537-26-000002 5783
2026-06-08 8-K 8-K 5.07 0001193125-26-261658 001-38662 261072496 34 145962 1 1
2026-06-02 4 xslF345X06/form4-06022026_080600.xml 0001761333-26-000005 7865
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001699737-26-000010 005-90656 26988892 34 18275
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001907884-26-000008 005-90656 26986633 34 9500
2026-05-14 10-Q 10-Q 0001193125-26-224170 001-38662 26979589 34 10807254 1 1
2026-05-14 8-K 8-K 2.02,9.01 0001193125-26-224065 001-38662 26979119 34 346351 1 1
2026-05-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001011438-26-000314 005-90656 26979039 34 9267
2026-05-01 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-002548 005-90656 26932601 34 17868
2026-04-22 ARS ARS 0001140361-26-016150 001-38662 26884579 34 5888099
2026-04-22 DEFA14A DEFA14A 0001193125-26-170441 001-38662 26883970 34 7302707 1 1
2026-04-22 DEF 14A DEF 14A 0001193125-26-170354 001-38662 26883732 34 14603911 1 1
2026-04-21 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-046182 005-90656 26880779 34 15587
2026-04-21 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-166842 005-90656 26879723 34 652813
2026-04-01 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001050 333-294541 26830456 33 1815
2026-04-01 424B3 424B3 0001193125-26-138220 333-294541 26829469 33 337009
2026-03-30 CORRESP filename1.htm 0001193125-26-131936 8311
2026-03-27 UPLOAD filename1.pdf 0000000000-26-003141 333-294541 40088
2026-03-23 S-3 S-3 0001193125-26-120004 333-294541 26783340 33 1120160 1 1
2026-03-23 S-8 S-8 0001193125-26-119971 333-294536 26783195 33 360539 1 1
2026-03-23 10-K 10-K 0001193125-26-119873 001-38662 26782976 34 18333819 1 1
2026-03-23 8-K 8-K 1.02,2.02,9.01 0001193125-26-119844 001-38662 26782714 34 346948 1 1
2026-03-06 4 xslF345X05/form4-03062026_090355.xml 0002063633-26-000003 8954
2026-03-06 4 xslF345X05/form4-03062026_090306.xml 0001872398-26-000003 8962
2026-03-03 4 xslF345X05/form4-03032026_110346.xml 0002063633-26-000002 23232
2026-03-03 4 xslF345X05/form4-03032026_110346.xml 0001992979-26-000002 19485
2026-03-03 4 xslF345X05/form4-03032026_110348.xml 0001761333-26-000002 8551
2026-03-03 4 xslF345X05/form4-03032026_110347.xml 0001872398-26-000002 22719
2026-02-18 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-26-000502 005-90656 26651035 34 38395
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-26-000954 005-90656 26634103 34 16291
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-26-000953 005-90656 26634085 34 16229
2026-02-10 8-K 8-K 1.01,7.01,9.01 0001193125-26-044934 001-38662 26617256 34 12853060 1 1
2026-02-10 424B5 424B5 0001193125-26-044923 333-275525 26617183 33 511127
2026-01-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001315863-26-000098 005-90656 26579985 34 15044
2026-01-20 144 xsl144X01/primary_doc.xml 0001950047-26-000550 001-38662 26543061 33 6523
2025-12-29 4 xslF345X05/form4-12292025_101249.xml 0001587487-25-000004 12468
2025-12-29 4 xslF345X05/form4-12292025_101202.xml 0001294939-25-000004 12460
2025-12-29 4 xslF345X05/form4-12292025_101218.xml 0001217412-25-000003 12530
2025-12-29 4 xslF345X05/form4-12292025_101213.xml 0001236537-25-000008 12437
2025-12-29 4 xslF345X05/form4-12292025_101215.xml 0001536193-25-000004 12507
2025-12-29 4 xslF345X05/form4-12292025_091244.xml 0001554591-25-000004 12491
2025-12-29 4 xslF345X05/form4-12292025_091243.xml 0001891841-25-000005 12494
2025-12-29 4 xslF345X05/form4-12292025_091245.xml 0001601264-25-000005 12484
2025-12-29 4 xslF345X05/form4-12292025_091213.xml 0002063633-25-000006 12478
2025-12-29 4 xslF345X05/form4-12292025_091224.xml 0001992979-25-000006 12734
2025-12-29 4 xslF345X05/form4-12292025_091238.xml 0001761333-25-000008 12806
2025-12-17 8-K 8-K 8.01 0001193125-25-322859 001-38662 251579837 34 131843 1 1
2025-12-16 4 xslF345X05/form4-12172025_011222.xml 0001872398-25-000005 16852
2025-12-03 8-K 8-K 3.03,5.03,8.01,9.01 0001193125-25-306786 001-38662 251546844 34 207657 1 1
2025-11-06 10-Q 10-Q 0001193125-25-270036 001-38662 251459396 34 13112947 1 1
2025-11-06 8-K 8-K 2.02,9.01 0001193125-25-269833 001-38662 251459209 34 307924 1 1
2025-10-23 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001999371-25-015943 005-90656 251413088 34 9355
2025-10-16 4 xslF345X05/form4-10162025_121041.xml 0001992979-25-000004 5259
2025-10-16 4 xslF345X05/form4-10162025_121041.xml 0001761333-25-000005 5236
2025-10-16 4 xslF345X05/form4-10162025_121000.xml 0001872398-25-000004 4695
2025-10-16 4 xslF345X05/form4-10162025_121046.xml 0001236537-25-000006 4622
2025-10-16 4 xslF345X05/form4-10162025_121018.xml 0002063633-25-000004 5014
2025-09-29 8-K 8-K 2.05,9.01 0001193125-25-223434 001-38662 251357270 34 177592 1 1
2025-09-22 4 xslF345X05/form4-09222025_090937.xml 0001992979-25-000003 9028
2025-09-12 3/A xslF345X02/form3a-09122025_080949.xml 0001415889-25-024376 4545
2025-08-26 4 xslF345X05/form4-08272025_010822.xml 0001415889-25-023084 9013
2025-08-26 4 xslF345X05/form4-08272025_010839.xml 0001415889-25-023083 9001
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-022031 005-90656 251221566 34 12725
2025-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-004735 005-90656 251213797 34 17524
2025-08-07 10-Q 10-Q 0000950170-25-105219 001-38662 251195158 34 13042383 1 1
2025-08-07 8-K 8-K 2.02,9.01 0000950170-25-105159 001-38662 251194934 34 333753 1 1
2025-07-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-001053 005-90656 251160688 34 6297
2025-07-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002548 005-90656 251128473 34 10863
2025-06-30 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-064161 005-90656 251092624 34 15238
2025-06-25 8-K 8-K 3.01 0000950170-25-089978 001-38662 251073985 34 166694 1 1
2025-06-10 8-K 8-K 5.07 0001193125-25-138481 001-38662 251037518 34 147259 1 1
2025-06-10 4 xslF345X05/form4-06102025_080610.xml 0001415889-25-016471 5630
2025-06-10 4 xslF345X05/form4-06102025_080628.xml 0001415889-25-016470 5629
2025-06-10 4 xslF345X05/form4-06102025_080644.xml 0001415889-25-016469 5644
2025-06-10 4 xslF345X05/form4-06102025_080602.xml 0001415889-25-016468 5609
2025-06-10 4 xslF345X05/form4-06102025_080614.xml 0001415889-25-016467 5664
2025-06-10 4 xslF345X05/form4-06102025_080630.xml 0001415889-25-016466 5665
2025-06-10 4 xslF345X05/form4-06102025_080632.xml 0001415889-25-016464 5666
2025-06-10 4 xslF345X05/form4-06102025_080619.xml 0001415889-25-016463 5664
2025-06-02 4 xslF345X05/form4-06022025_080648.xml 0001415889-25-015142 8077
2025-06-02 3 xslF345X02/form3-06022025_080656.xml 0001415889-25-015141 10330
2025-06-02 8-K 8-K 5.02 0001193125-25-133268 001-38662 251014789 34 140659 1 1
2025-05-30 S-8 S-8 0000950170-25-079768 333-287688 251011469 33 755246 1 1
2025-05-19 4 xslF345X05/form4-05192025_080539.xml 0001415889-25-013618 16937
2025-05-15 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001085146-25-003248 005-90656 25950253 34 9300
2025-05-08 10-Q 10-Q 0000950170-25-067072 001-38662 25926773 34 11105741 1 1
2025-05-08 8-K 8-K 2.02,9.01 0000950170-25-067061 001-38662 25926715 34 398276 1 1
2025-05-05 4 xslF345X05/form4-05052025_090517.xml 0001415889-25-011998 21565
2025-05-05 4 xslF345X05/form4-05052025_090515.xml 0001415889-25-011997 8972
2025-05-05 4 xslF345X05/form4-05052025_090507.xml 0001415889-25-011996 13366
2025-04-25 ARS ARS 0001140361-25-015788 001-38662 25874678 34 2830726
2025-04-25 DEFA14A DEFA14A 0000950170-25-058787 001-38662 25874670 34 5309077 1 1
2025-04-25 DEF 14A DEF 14A 0000950170-25-058774 001-38662 25874584 34 13665920 1 1
2025-04-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001576419-25-000809 005-90656 25844743 34 10905
2025-04-15 4 xslF345X05/form4-04152025_080443.xml 0001415889-25-010683 8980
2025-04-14 PRE 14A PRE 14A 0000950170-25-053739 001-38662 25836431 34 13664971 1 1
2025-04-14 8-K 8-K 5.02 0000950170-25-053733 001-38662 25836369 34 152701 1 1
2025-04-08 4 xslF345X05/form4-04082025_080404.xml 0001415889-25-010385 8108
2025-04-08 4 xslF345X05/form4-04082025_080457.xml 0001415889-25-010384 8133
2025-04-08 4 xslF345X05/form4-04082025_080432.xml 0001415889-25-010383 8125
2025-04-08 4 xslF345X05/form4-04082025_080441.xml 0001415889-25-010382 8132
2025-04-08 4 xslF345X05/form4-04082025_080422.xml 0001415889-25-010381 8083
2025-04-08 3 xslF345X02/form3-04082025_080433.xml 0001415889-25-010380 24446
2025-04-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-010207 005-90656 25815384 34 18777
2025-03-13 10-K 10-K 0000950170-25-038884 001-38662 25736870 34 17691067 1 1
2025-03-13 8-K 8-K 2.02,2.05,5.02,9.01 0000950170-25-038879 001-38662 25736814 34 474752 1 1
2025-03-07 4 xslF345X05/form4-03072025_090322.xml 0001415889-25-007405 9843
2025-03-07 4 xslF345X05/form4-03072025_090312.xml 0001415889-25-007398 9965
2025-03-07 4 xslF345X05/form4-03072025_090300.xml 0001415889-25-007393 8778
2025-03-06 4 xslF345X05/form4-03062025_090345.xml 0001415889-25-007185 8781
2025-03-06 4 xslF345X05/form4-03062025_090328.xml 0001415889-25-007184 9968
2025-03-06 4 xslF345X05/form4-03062025_090325.xml 0001415889-25-007183 9848
2025-03-06 4 xslF345X05/form4-03062025_090350.xml 0001415889-25-007182 8958
2025-03-04 4 xslF345X05/form4-03042025_110314.xml 0001415889-25-006714 12548
2025-03-04 4 xslF345X05/form4-03042025_110302.xml 0001415889-25-006712 12723
2025-03-04 4 xslF345X05/form4-03042025_110358.xml 0001415889-25-006709 14122
2025-03-04 4 xslF345X05/form4-03042025_110331.xml 0001415889-25-006696 8993
2025-03-04 4 xslF345X05/form4-03042025_110305.xml 0001415889-25-006690 13613
2025-03-04 4 xslF345X05/form4-03042025_100339.xml 0001415889-25-006656 12751
2025-03-04 4 xslF345X05/form4-03042025_100306.xml 0001415889-25-006655 14294
2025-02-27 S-8 S-8 0000950170-25-029118 333-285346 25679584 33 371510 1 1
2024-12-10 8-K 8-K 8.01 0000950170-24-134765 001-38662 241537152 34 158581 1 1
2024-12-03 4 xslF345X05/form4-12032024_091242.xml 0001415889-24-028066 8966
2024-11-14 SC 13G/A SUTRO BIOPHARMA, INC. 0000902664-24-006662 005-90656 241465327 34 76160
2024-11-14 SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G 0000921895-24-002724 005-90656 241463155 34 266576
2024-11-13 10-Q 10-Q 0000950170-24-126407 001-38662 241454991 34 10686360 1 1
2024-11-13 SC 13G/A SC 13G/A 0001104659-24-117750 005-90656 241454871 34 73210
2024-11-13 8-K 8-K 2.02,9.01 0000950170-24-126382 001-38662 241454826 34 372121 1 1
2024-11-12 SC 13G/A UnitedStates_13G__SutroBioph.txt 0000932471-24-001222 005-90656 241450200 34 6623
2024-11-12 SC 13G/A p24-3036sc13ga.htm 0000902664-24-006411 005-90656 241444238 34 72981
2024-11-04 SC 13G/A STRO_SC13GA1_2024.htm 0001319244-24-000056 005-90656 241423530 34 95764
2024-11-04 SC 13G/A UnitedStates_13G__SutroBioph.txt 0000932471-24-000748 005-90656 241422561 34 5677
2024-09-20 4 xslF345X05/form4-09202024_080944.xml 0001415889-24-023745 9039
2024-08-13 10-Q 10-Q 0000950170-24-096336 001-38662 241202202 34 10629272 1 1
2024-08-13 8-K 8-K 2.02,9.01 0000950170-24-096313 001-38662 241202115 34 366599 1 1
2024-08-13 4 xslF345X05/form4-08132024_080852.xml 0001415889-24-021157 9008
2024-08-12 4 xslF345X05/form4-08122024_080817.xml 0001415889-24-021089 8137
2024-08-12 3 xslF345X02/form3-08122024_080821.xml 0001415889-24-021088 10598
2024-08-12 8-K 8-K 5.02 0000950170-24-095486 001-38662 241197187 34 152379 1 1
2024-07-10 4 xslF345X05/form4-07102024_080725.xml 0001415889-24-019462 8128
2024-07-10 3 xslF345X02/form3-07102024_080709.xml 0001415889-24-019461 10750
2024-06-10 4 xslF345X05/form4-06102024_080603.xml 0001415889-24-016228 5632
2024-06-10 8-K 8-K 5.07 0000950170-24-071335 001-38662 241033160 34 176642 1 1
2024-06-10 4 xslF345X05/form4-06102024_080652.xml 0001415889-24-016227 5631
2024-06-10 4 xslF345X05/form4-06102024_080628.xml 0001415889-24-016223 5646
2024-06-10 4 xslF345X05/form4-06102024_080611.xml 0001415889-24-016219 5611
2024-06-10 4 xslF345X05/form4-06102024_080623.xml 0001415889-24-016216 5666
2024-06-10 4 xslF345X05/form4-06102024_080615.xml 0001415889-24-016211 5668
2024-06-10 4 xslF345X05/form4-06102024_080606.xml 0001415889-24-016209 5656
2024-06-10 4 xslF345X05/form4-06102024_080625.xml 0001415889-24-016204 5666
2024-05-17 DEFA14A DEFA14A 0001193125-24-141843 001-38662 24961074 34 14108
2024-05-13 10-Q 10-Q 0000950170-24-058718 001-38662 24939657 34 10456682 1 1
2024-05-13 8-K 8-K 2.02,9.01 0000950170-24-058701 001-38662 24939549 34 363824 1 1
2024-05-03 4 xslF345X05/form4-05032024_080512.xml 0001415889-24-012170 8986
2024-04-26 ARS ARS 0001140361-24-022513 001-38662 24884509 34 3984540
2024-04-26 DEF 14A DEF 14A 0000950170-24-049207 001-38662 24884354 34 2244993 1 1
2024-04-26 DEFA14A DEFA14A 0000950170-24-049212 001-38662 24884341 34 4011858
2024-04-12 4 xslF345X05/form4-04122024_090423.xml 0001415889-24-010772 8995
2024-04-05 SC 13G p24-1385sc13g.htm 0000902664-24-002770 005-90656 24826488 34 84331
2024-04-02 8-K 8-K 1.01,9.01 0000950170-24-040345 001-38662 24815468 34 702418 1 1
2024-04-02 424B5 424B5 0001193125-24-084879 333-275525 24815294 33 407210
2024-04-02 8-K 8-K 1.01,3.02,7.01,9.01 0000950170-24-039736 001-38662 24812110 34 238142 1 1
2024-03-25 10-K 10-K 0000950170-24-035949 001-38662 24779614 34 17913546 1 1
2024-03-25 8-K 8-K 2.02,9.01 0000950170-24-035948 001-38662 24779578 34 357391 1 1
2024-03-22 4/A xslF345X05/form4a-03222024_080335.xml 0001415889-24-008954 5918
2024-03-22 4/A xslF345X05/form4a-03222024_080326.xml 0001415889-24-008953 5974
2024-03-22 4/A xslF345X05/form4a-03222024_080309.xml 0001415889-24-008952 5782
2024-03-07 4 xslF345X05/form4-03082024_120344.xml 0001415889-24-007222 19101
2024-03-07 4 xslF345X05/form4-03072024_090338.xml 0001415889-24-007189 8116
2024-03-07 4 xslF345X05/form4-03072024_090300.xml 0001415889-24-007188 14560
2024-03-07 4 xslF345X05/form4-03072024_090326.xml 0001415889-24-007184 8114
2024-03-07 4 xslF345X05/form4-03072024_090340.xml 0001415889-24-007183 8087
2024-03-07 4 xslF345X05/form4-03072024_090326.xml 0001415889-24-007182 8092
2024-03-07 4 xslF345X05/form4-03072024_090345.xml 0001415889-24-007181 13489
2024-03-06 4 xslF345X05/form4-03062024_090306.xml 0001415889-24-007039 9847
2024-03-06 4 xslF345X05/form4-03062024_090303.xml 0001415889-24-007030 9969
2024-03-06 4 xslF345X05/form4-03062024_090325.xml 0001415889-24-007020 8958
2024-03-06 4 xslF345X05/form4-03062024_090307.xml 0001415889-24-007012 8782
2024-03-05 4 xslF345X05/form4-03052024_090304.xml 0001415889-24-006738 8996
2024-03-05 4 xslF345X05/form4-03052024_090358.xml 0001415889-24-006725 9852
2024-03-05 4 xslF345X05/form4-03052024_090313.xml 0001415889-24-006712 9974
2024-03-05 4 xslF345X05/form4-03052024_090320.xml 0001415889-24-006687 8964
2024-03-05 4 xslF345X05/form4-03052024_090359.xml 0001415889-24-006651 8786
2024-03-04 4 xslF345X05/form4-03042024_090339.xml 0001415889-24-006267 9019
2024-02-27 S-8 S-8 0000950170-24-021231 333-277404 24687494 33 190594
2024-02-13 SC 13G/A d10963170_13g-a.htm 0000919574-24-000959 005-90656 24623905 34 120547
2024-02-12 SC 13G/A SC 13G/A 0001104659-24-013564 005-90656 24617237 34 73936
2024-02-09 8-K 8-K 8.01,9.01 0001193125-24-030094 001-38662 24615432 34 432697 1 1
2024-02-09 424B5 424B5 0001193125-24-030080 333-275525 24615405 33 344481
2024-02-07 SC 13G/A SUTRO BIOPHARMA, INC. 0000902664-24-001187 005-90656 24602219 34 94751
2024-01-31 4 xslF345X05/form4-01312024_090125.xml 0001415889-24-002072 9835
2024-01-31 4 xslF345X05/form4-01312024_090157.xml 0001415889-24-002071 8769
2024-01-31 4 xslF345X05/form4-01312024_090153.xml 0001415889-24-002067 9957
2024-01-31 4 xslF345X05/form4-01312024_090124.xml 0001415889-24-002065 10667
2024-01-29 144 xsl144X01/primary_doc.xml 0001950047-24-000502 001-38662 24574629 33 7215
2024-01-24 SC 13G/A us8693671021_012424.txt 0001086364-24-002697 005-90656 24557789 34 13509
2024-01-17 SC 13G STRO_SC13G_2024.htm 0001319244-24-000003 005-90656 24539106 34 95860
2024-01-08 8-K 8-K 2.02,7.01,8.01,9.01 0000950170-24-002690 001-38662 24518342 34 18905005 1 1
2023-12-04 4 FORM 4 SUBMISSION 0001209191-23-057206 8110
2023-11-27 8-K 8-K 1.01 0000950170-23-066112 001-38662 231440313 34 167002 1 1
2023-11-21 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-11-21 16:00:00 9999999995-23-003414 333-275525 231429873 33 1774
2023-11-21 8-K 8-K 5.02,7.01,9.01 0000950170-23-065482 001-38662 231428050 34 190285 1 1
2023-11-17 CORRESP filename1.htm 0001193125-23-279783 8421
2023-11-16 UPLOAD filename1.pdf 0000000000-23-012595 40339
2023-11-13 S-3 S-3 0001193125-23-276208 333-275525 231400097 33 745606
2023-11-13 10-Q 10-Q 0000950170-23-063037 001-38662 231399402 34 13125161 1 1
2023-11-13 8-K 8-K 2.02,9.01 0000950170-23-063021 001-38662 231399295 34 438592 1 1
2023-10-10 SC 13G SUTRO BIOPHARMA, INC. 0000902664-23-005066 005-90656 231318509 34 100382
2023-10-04 8-K 8-K 1.01 0000950170-23-051917 001-38662 231308410 34 166716 1 1
2023-09-19 4 FORM 4 SUBMISSION 0001209191-23-049943 8153
2023-09-19 3 FORM 3 SUBMISSION 0001209191-23-049933 6957
2023-08-29 4 FORM 4 SUBMISSION 0001209191-23-047608 5580
2023-08-28 4 FORM 4 SUBMISSION 0001209191-23-047512 5224
2023-08-25 144 xsl144X01/primary_doc.xml 0001972362-23-000707 001-38662 231209016 33 8378
2023-08-11 4 FORM 4 SUBMISSION 0001209191-23-045434 9117
2023-08-10 10-Q 10-Q 0000950170-23-041416 001-38662 231160122 34 14661738 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-041404 001-38662 231160084 34 485067 1 1
2023-07-13 4 FORM 4 SUBMISSION 0001209191-23-042244 9131
2023-06-29 4 FORM 4 SUBMISSION 0001209191-23-040213 6508
2023-06-26 8-K 8-K 1.01 0000950170-23-029731 001-38662 231039459 34 172512 1 1
2023-06-14 8-K 8-K 1.02,5.07 0000950170-23-027975 001-38662 231014537 34 220730 1 1
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036479 5590
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036474 5554
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036473 5553
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036472 5568
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036471 5533
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036470 5588
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036467 5572
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036466 5588
2023-05-15 10-Q 10-Q 0000950170-23-021976 001-38662 23918530 34 11853295 1 1
2023-05-15 8-K 8-K 2.02,9.01 0000950170-23-021973 001-38662 23918502 34 475865 1 1
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026736 8129
2023-05-02 3 FORM 3 SUBMISSION 0001209191-23-026700 12677
2023-04-28 ARS ARS 0001140361-23-021534 001-38662 23866177 34 1923954
2023-04-28 DEFA14A DEFA14A 0000950170-23-015774 001-38662 23865972 34 1860101
2023-04-28 DEF 14A DEF 14A 0000950170-23-015762 001-38662 23865831 34 3099417
2023-04-27 8-K 8-K 5.02 0000950170-23-015323 001-38662 23857633 34 165754 1 1
2023-04-17 4 FORM 4 SUBMISSION 0001209191-23-024550 9084
2023-04-14 8-K 8-K 5.02 0000950170-23-012879 001-38662 23821178 34 168219 1 1
2023-04-14 PRE 14A PRE 14A 0000950170-23-012876 001-38662 23821152 34 3098370
2023-03-30 8-K 8-K 2.02,9.01 0000950170-23-010978 001-38662 23781152 34 460057 1 1
2023-03-30 10-K 10-K 0000950170-23-010976 001-38662 23781150 34 19782475 1 1
2023-03-17 4 FORM 4 SUBMISSION 0001209191-23-019599 8144
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016818 17755
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016809 18632
2023-03-07 3 FORM 3 SUBMISSION 0001209191-23-016804 15728
2023-03-07 3 FORM 3 SUBMISSION 0001209191-23-016798 7516
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016794 17761
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016751 17751
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016747 18745
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016742 13856
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016739 15384
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016736 17557
2023-02-27 S-8 S-8 0000950170-23-004676 333-270055 23675506 33 469122
2023-02-24 8-K 8-K 5.03,9.01 0000950170-23-004373 001-38662 23667049 34 595800 1 1
2023-02-14 4 FORM 4 SUBMISSION 0001209191-23-009236 6759
2023-02-14 SC 13G/A SC 13G/A 0001580642-23-000874 005-90656 23627645 34 57591
2023-02-14 SC 13G/A AMENDMENT NO. 1 TO THE SCHEDULE 13G 0000921895-23-000524 005-90656 23624973 34 277068
2023-02-13 SC 13G/A d9928770_13g-a.htm 0000919574-23-000973 005-90656 23615627 34 108552
2023-02-10 SC 13G SC 13G 0001104659-23-018473 005-90656 23611630 34 81962
2023-02-07 SC 13G/A us8693671021_020723.txt 0001306550-23-008351 005-90656 23594597 34 13290
2023-02-01 SC 13G/A sutr22a11.htm 0000038777-23-000037 005-90656 23575863 34 194933
2023-01-31 4 FORM 4 SUBMISSION 0001209191-23-005765 10112
2023-01-31 4 FORM 4 SUBMISSION 0001209191-23-005762 10047
2023-01-31 4 FORM 4 SUBMISSION 0001209191-23-005759 9052
2023-01-31 4 FORM 4 SUBMISSION 0001209191-23-005757 9066
2023-01-31 4 FORM 4 SUBMISSION 0001209191-23-005754 9163
2023-01-31 4 FORM 4 SUBMISSION 0001209191-23-005751 8862
2023-01-23 SC 13G/A STRO_SC13GA_2023.htm 0001273087-23-000051 005-90656 23544847 34 81728
2023-01-09 8-K 8-K 7.01,8.01,9.01 0000950170-23-000528 001-38662 23518903 34 27048490 1 1
2022-12-20 8-K 8-K 1.01 0000950170-22-026823 001-38662 221474815 34 174115 1 1
2022-11-08 10-Q 10-Q 0000950170-22-023279 001-38662 221369442 34 13907810 1 1
2022-11-08 8-K 8-K 2.02,9.01 0000950170-22-023274 001-38662 221369402 34 479339 1 1
2022-10-24 8-K 8-K 5.02 0000950170-22-019872 001-38662 221324812 34 166922 1 1
2022-08-31 S-8 S-8 0000950170-22-017978 333-267194 221218335 33 489842
2022-08-10 4 FORM 4 SUBMISSION 0001209191-22-045297 9262
2022-08-08 10-Q 10-Q 0000950170-22-015584 001-38662 221145036 34 14598680 1 1
2022-08-08 8-K 8-K 2.02,9.01 0000950170-22-015573 001-38662 221144874 34 453792 1 1
2022-07-26 8-K 8-K 8.01 0000950170-22-013078 001-38662 221107131 34 173737 1 1
2022-07-13 4 FORM 4 SUBMISSION 0001209191-22-042072 9064
2022-07-08 SC 13G STRO_SC13G.htm 0001273087-22-000089 005-90656 221074605 34 81667
2022-06-28 8-K 8-K 1.01,8.01,9.01 0000950170-22-012215 001-38662 221046161 34 3491769 1 1
2022-06-16 8-K 8-K 8.01,9.01 0000950170-22-011712 001-38662 221019314 34 3226284 1 1
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035213 5523
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035212 5550
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035211 5522
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035210 5537
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035209 5502
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035208 5557
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035207 5559
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035206 5557
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-035205 5541
2022-06-07 8-K 8-K 5.07 0000950170-22-011282 001-38662 221001807 34 213359 1 1
2022-05-19 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-22-058489,2022-05-19 9999999995-22-001527 333-255014 22945184 33 1786
2022-05-18 POS EX POS EX 0001564590-22-020653 333-255014 22939080 33 350376
2022-05-09 10-Q 10-Q 0000950170-22-008531 001-38662 22905616 34 10840764 1 1
2022-05-09 8-K 8-K 2.02,9.01 0000950170-22-008525 001-38662 22905539 34 388095 1 1
2022-04-25 DEFA14A DEFA14A 0000950170-22-006032 001-38662 22847079 34 1132954
2022-04-25 DEF 14A DEF 14A 0000950170-22-006031 001-38662 22847070 34 1911049
2022-04-20 8-K 8-K 1.01 0000950170-22-005825 001-38662 22836307 34 162455 1 1
2022-04-15 4 FORM 4 SUBMISSION 0001209191-22-024540 9051
2022-03-15 4 FORM 4 SUBMISSION 0001209191-22-018969 6991
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016865 8073
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016858 14872
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016856 15682
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016855 13888
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016854 13877
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016853 13850
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016850 13985
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016846 13684
2022-03-01 S-8 S-8 0001193125-22-058562 333-263113 22692299 33 86504
2022-03-01 POS AM POS AM 0001193125-22-058489 333-255014 22692053 33 459708
2022-02-28 8-K 8-K 2.02,9.01 0000950170-22-002316 001-38662 22690404 34 449669 1 1
2022-02-28 10-K 10-K 0000950170-22-002312 001-38662 22690246 34 19621568 1 1
2022-02-28 POSASR POSASR 0001193125-22-057928 333-255014 22689794 33 520724
2022-02-14 SC 13G/A SC 13G/A 0001580642-22-000833 005-90656 22627754 34 56126
2022-02-11 SC 13G/A d9172357_13g-a.htm 0000919574-22-000912 005-90656 22622104 34 111148
2022-02-09 4 FORM 4 SUBMISSION 0001209191-22-008198 26219
2022-02-04 SC 13G sutr21in.htm 0000038777-22-000039 005-90656 22592422 34 207387
2022-02-03 SC 13G/A us8693671021_020222.txt 0000834237-22-005489 005-90656 22585821 34 13382
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006131 10049
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006129 9065
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006128 10853
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006127 9021
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006125 9054
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006121 9164
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006119 8864
2022-01-18 SC 13G THE SCHEDULE 13G 0000921895-22-000169 005-90656 22535981 34 285212
2022-01-10 8-K 8-K 7.01,9.01 0000950170-22-000168 001-38662 22519628 34 2905216 1 1
2022-01-05 8-K 8-K 7.01,8.01,9.01 0000950170-22-000081 001-38662 22512428 34 1833862 1 1
2022-01-03 4 FORM 4 SUBMISSION 0001209191-22-000329 8897
2021-12-27 8-K 8-K 1.01 0000950170-21-005353 001-38662 211518901 34 168901 1 1
2021-12-10 SC 13G d9080302_13g.htm 0000919574-21-007392 005-90656 211485787 34 105911
2021-11-22 4 FORM 4 SUBMISSION 0001209191-21-066150 8093
2021-11-22 3 FORM 3 SUBMISSION 0001209191-21-066148 7428
2021-11-17 8-K 8-K 5.02 0001564590-21-057374 001-38662 211418393 34 162797 1 1
2021-11-10 8-K 8-K 2.02,7.01,9.01 0001564590-21-055917 001-38662 211394349 34 9367690 1 1
2021-11-10 10-Q 10-Q 0001564590-21-055843 001-38662 211393633 34 12801645 1 1
2021-10-12 8-K 8-K 1.01 0001564590-21-050583 001-38662 211316847 34 162544 1 1
2021-09-30 8-K 8-K_MERCKAMEND 8.01 0001564590-21-049553 001-38662 211293562 34 200535 1 1
2021-09-28 4 FORM 4 SUBMISSION 0001209191-21-057982 11330
2021-09-28 4 FORM 4 SUBMISSION 0001209191-21-057981 14520
2021-09-28 4 FORM 4 SUBMISSION 0001209191-21-057980 9028
2021-09-28 4 FORM 4 SUBMISSION 0001209191-21-057978 9064
2021-09-28 4 FORM 4 SUBMISSION 0001209191-21-057977 10056
2021-09-28 4 FORM 4 SUBMISSION 0001209191-21-057976 9172
2021-09-28 4 FORM 4 SUBMISSION 0001209191-21-057975 8871
2021-08-11 3 FORM 3 SUBMISSION 0001209191-21-050957 21080
2021-08-11 4 FORM 4 SUBMISSION 0001209191-21-050956 8148
2021-08-11 3 FORM 3 SUBMISSION 0001209191-21-050947 7478
2021-08-09 8-K 8-K 2.02,9.01 0001564590-21-042330 001-38662 211154567 34 406188 1 1
2021-08-09 10-Q 10-Q 0001564590-21-042217 001-38662 211154005 34 11915451 1 1
2021-08-09 S-8 S-8_INDUCEMENTPLAN 0001564590-21-042216 333-258603 211154002 33 381175
2021-06-17 8-K 8-K 1.01,2.03 0001564590-21-033400 001-38662 211025979 34 167456 1 1
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038701 5532
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038699 5559
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038692 5531
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038688 5546
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038685 5511
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038682 5566
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038680 5546
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038677 5566
2021-06-04 8-K 8-K 5.07 0001564590-21-031670 001-38662 21994832 34 180938 1 1
2021-05-19 8-K 8-K 7.01,9.01 0001564590-21-028892 001-38662 21941040 34 9390919 1 1
2021-05-07 8-K 8-K 2.02,9.01 0001564590-21-025294 001-38662 21900179 34 372076 1 1
2021-05-07 10-Q 10-Q 0001564590-21-025155 001-38662 21899384 34 9924057 1 1
2021-04-29 DEF 14A DEF 14A 0001564590-21-022043 001-38662 21871765 34 1916665
2021-04-20 4 FORM 4 SUBMISSION 0001209191-21-027600 8101
2021-04-15 8-K 8-K 8.01 0001564590-21-018899 001-38662 21827258 34 168518 1 1
2021-04-05 SC 13G/A SCHEDULE 13G/A 0001140361-21-011664 005-90656 21806786 34 88070
2021-04-02 S-3ASR S-3ASR 0001193125-21-105216 333-255014 21802677 33 978610
2021-03-18 S-8 S-8 0001564590-21-014197 333-254456 21755090 33 187803
2021-03-18 8-K 8-K 2.02,9.01 0001564590-21-014003 001-38662 21753052 34 387163 1 1
2021-03-18 10-K 10-K 0001564590-21-013945 001-38662 21752269 34 16192501 1 1
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018623 8044
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018622 8067
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018620 8090
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018619 8102
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018618 8211
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018617 7910
2021-02-16 SC 13G/A SC 13G/A 0001104659-21-024120 005-90656 21639244 34 237109
2021-02-16 SC 13G/A SC 13G/A 0001104659-21-024074 005-90656 21638926 34 93570
2021-02-16 SC 13G/A SC 13G/A 0001104659-21-023106 005-90656 21633030 34 78729

Latest XBRL company facts

One latest value per concept from companyfacts (275 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 16.60M 2026-11-06 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
dei EntityPublicFloat Entity Public Float USD 60.00M 2025-06-30 2025 FY 10-K 2026-03-23 0001193125-26-119873
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 895.76M 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170354
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 898.71M 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170354
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 14 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170354
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.84M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AccountsReceivableNet Accounts Receivable, after Allowance for Credit Loss USD 2.49M 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 12.81M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AccountsReceivableRelatedPartiesCurrent Accounts Receivable, Related Parties, Current USD 0 2020-12-31 2020 FY 10-K 2021-03-18 0001564590-21-013945
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AccretionExpense Accretion Expense USD 42,000 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-15 0001564590-19-019236
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 0 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 7.76M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 27.35M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -77,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 953.99M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Share-based Payment Arrangement, Decrease for Tax Withholding Obligation USD 20,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.16M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 734,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-18 0001564590-21-013945
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 5.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 300,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 1.85M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 1.69M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap Assets Assets USD 176.65M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AssetsCurrent Assets, Current USD 159.50M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 78,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 141.72M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss USD 85.70M 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-055843
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 141.65M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap BusinessExitCosts1 Business Exit Costs USD 259,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 176,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 46.85M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations USD 19.41M 2019-06-30 2019 Q2 10-Q 2019-08-14 0001564590-19-031883
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -105.91M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-14 0001564590-19-031883
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 47.71M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 47.71M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -11.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 3.33M 2017-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 2.38M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 16.60M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 16.60M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CommonStockValue Common Stock, Value, Issued USD 17,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -108.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 8.27M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 1.78M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption Cumulative Effect of New Accounting Principle in Period of Adoption (Deprecated 2020-01-31) USD 10.33M 2019-03-31 2019 Q3 10-Q 2019-11-08 0001564590-19-041909
us-gaap CumulativeEffectOnRetainedEarningsNetOfTax1 Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) USD 10.33M 2019-01-01 2019-03-31 2020 Q2 10-Q 2020-08-06 0001564590-20-036997
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 2.24M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 943,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD -93,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD -93,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DebtCurrent Debt, Current USD 4.06M 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 3.13M 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap DebtInstrumentInterestRateDuringPeriod Debt Instrument, Interest Rate During Period pure 0.115 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount USD 276,000 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD -936,000 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 25.90M 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-270036
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 36,000 2017-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 1.34M 2020-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 24.23M 2018-09-30 2018 Q3 10-Q 2018-11-14 0001564590-18-029555
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 48.80M 2018-09-30 2018 Q3 10-Q 2018-11-14 0001564590-18-029555
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 2.59M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 274.90M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 71.49M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 2.70M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 87.27M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 51.99M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 4.61M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 6.86M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 272.20M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 2.70M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DeferredTaxLiabilitiesInvestments Deferred Tax Liabilities, Investments USD 7.38M 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 398,000 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 600,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 3.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -7.03 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.84 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008531
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -7.03 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.221 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure -0.634 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap EffectiveIncomeTaxRateReconciliationFdiiPercent EffectiveIncomeTaxRateReconciliationFdiiPercent pure -0.014 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.001 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount USD 2.04M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.011 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.022 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EquitySecuritiesFvNi Equity Securities, FV-NI USD 41.94M 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap EquitySecuritiesFvNiRealizedGainLoss Equity Securities, FV-NI, Realized Gain (Loss) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap EquitySecuritiesFvNiUnrealizedGainLoss Equity Securities, FV-NI, Unrealized Gain (Loss) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap FairValueLiabilitiesLevel1ToLevel2TransfersAmount Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount USD 0 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap FairValueLiabilitiesLevel2ToLevel1TransfersAmount Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount USD 0 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap ForeignCurrencyTransactionGainLossAfterTax ForeignCurrencyTransactionGainLossAfterTax USD 200,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ForeignIncomeTaxExpenseBenefitContinuingOperations Foreign Income Tax Expense (Benefit), Continuing Operations USD 2.50M 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap GainLossOnContractTermination Gain (Loss) on Contract Termination USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD -275,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 22.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ImpairmentOfLeasehold Impairment of Leasehold USD 200,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of USD 1.60M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -191.18M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -108.52M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD -14,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD -14,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 42.26M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -40.15M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 148,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -93,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD -99,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 4.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -4.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 8.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -2.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncreaseDecreaseInDeferredCharges Increase (Decrease) in Deferred Charges USD -931,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-30 0000950170-23-010976
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 49.17M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-14 0001564590-18-029555
us-gaap IncreaseDecreaseInEmployeeRelatedLiabilities Increase (Decrease) in Employee Related Liabilities USD -6.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -5.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 1.33M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0000950170-22-023279
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 475,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap InterestExpense Interest Expense USD 1.62M 2018-01-01 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap InterestExpenseDebt Interest Expense, Debt USD 1.30M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD -4.35M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap InterestPayableCurrentAndNoncurrent Interest Payable USD 100,000 2023-09-30 2023 Q3 10-Q 2023-11-13 0000950170-23-063037
us-gaap InvestmentIncomeNonoperating Investment Income, Nonoperating USD 4.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap InvestmentOwnedAtFairValue Investment Owned, at Fair Value USD 0 2024-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap LaborAndRelatedExpense Labor and Related Expense USD 39.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LeaseCost Lease, Cost USD 7.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 10.32M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 8.29M 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 8.29M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 8.29M 2022-12-31 2022 FY 10-K 2023-03-30 0000950170-23-010976
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 8.29M 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 8.29M 2024-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038884
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 8.29M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 2.04M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 625,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap Liabilities Liabilities USD 309.18M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 176.65M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LiabilitiesCurrent Liabilities, Current USD 54.31M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap LongTermDebt Long-term Debt USD 4.06M 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 4.06M 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 13.31M 2022-12-31 2022 FY 10-K 2023-03-30 0000950170-23-010976
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 4.13M 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 4.13M 2022-12-31 2022 FY 10-K 2023-03-30 0000950170-23-010976
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 0 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap LossOnContractTermination Loss on Contract Termination USD 9.83M 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-07 0000950170-25-105219
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 95.33M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 102.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -11.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -103.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -108.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -19.59M 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-11 0001564590-20-023689
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -27.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingExpenses Operating Expenses USD 114.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -81.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeaseCost Operating Lease, Cost USD 4.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 4.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 9.70M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 7.61M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 2.09M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeasePayments Operating Lease, Payments USD 7.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 7.18M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 48.74M 2020-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 5.74M 2020-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 7.48M 2020-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 6.31M 2020-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 5.18M 2020-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 4.70M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-30 0000950170-23-010976
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.108 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 1.98M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -96,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 2.64M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 1.69M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -336,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 1.91M 2018-01-01 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-13 0000950170-24-058718
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 7,000 2021-01-01 2021-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap PaymentsForRestructuring Payments for Restructuring USD 2.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 170,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 0 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-08 0001564590-19-041909
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 22,000 2022-01-01 2022-03-31 2023 Q1 10-Q 2023-05-15 0000950170-23-021976
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 180,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 184.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 763,000 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-11 0001564590-20-023689
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 4.51M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 103.13M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-224170
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 102.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 25.00M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-30 0000950170-23-010976
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 15.00M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 10.00M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-18 0001564590-21-013945
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 84.74M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-18 0001564590-21-013945
us-gaap ProceedsFromSaleOfEquitySecuritiesFvNi ProceedsFromSaleOfEquitySecuritiesFvNi USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 84,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 228,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 2,000 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-14 0001564590-18-029555
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -108.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 38.00M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 7.13M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock Receivable from Officers and Directors for Issuance of Capital Stock USD 208,000 2017-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap RepaymentsOfDebt Repayments of Debt USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 91.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 858,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RestructuringAndRelatedCostIncurredCost Restructuring and Related Cost, Incurred Cost USD 9.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RestructuringCharges Restructuring Charges USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-224170
us-gaap RestructuringCosts Restructuring Costs USD 259,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RestructuringReserve Restructuring Reserve USD 275,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RestructuringReserveCurrent Restructuring Reserve, Current USD 9.89M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.09B 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 33.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap Revenues Revenues USD 11.30M 2019-10-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap SeveranceCosts1 Severance Costs USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 5.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.819 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008531
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.943 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.845 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.017 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008531
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.042 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.035 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 30,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 266,724 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 6.08 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares shares 4,445 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 4,445 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-055843
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 1.10M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 210,000 2018-01-01 2018-12-31 2019 Q1 10-Q 2019-05-15 0001564590-19-019236
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 197,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -132.54M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.1 2025-12-02 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 262,279 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002312
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 187.24M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-18 0001564590-21-013945
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 147,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 24.57M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 1,000 2025-04-01 2025-06-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 6,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value USD 7,000 2021-01-01 2021-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035949
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 102.50M 2017-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 102.99M 2017-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 177.08M 2017-12-31 2018 FY 10-K 2019-04-01 0001564590-19-010253
us-gaap UnrealizedGainLossOnDerivativesAndCommodityContracts Unrealized Gain (Loss) on Derivatives and Commodity Contracts USD -7,000 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-11 0001564590-20-023689
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 13.43M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 17,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010890
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0000950170-23-010976
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 1.77M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 13.40M 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 44.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-23 0001193125-26-119873
us-gaap VariableLeaseCost Variable Lease, Cost USD 2.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 15.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 46.50M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008531
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 15.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458680

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →